Bavarian eases up on categorical statements on Covid-19 vaccine financing

Up until now, Bavarian Nordic's management has been adamant that it would only take the clinical development of the company's Covid-19 vaccine further if money came in from outside, but CEO Paul Chaplin might be starting to change his tune.

Bavarian Nordic President & CEO Paul Chaplin | Photo: Bavarian Nordic / PR

The Covid-19 situation has changed significantly since Bavarian Nordic made a deal with Adaptvac for the latter's coronavirus vaccine just under a year ago.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs